Abstract
Although sex hormone replacement therapy (HRT) for postmenopausal women has been a standard practice for many years, the idea that an older man might be sex hormone deficient and might benefit from placement therapy has gained significant medical interest only within the past 10–15 years. The first modern era studies of male HRT were reported about a decade ago (1,2), and there are, as yet, no large multicenter randomized placebo controlled trials of male HRT. In addition, there currently is no agreement on what hormonal or clinical criteria should be used to decide which older men might be considered “androgen deficient” and candidates for HRT. The lack of consensus, however, has not lessened the public and media interest in this topic. Testosterone sales, at least in the United States, continue to increase. At the same time, how to identify [partial]androgen deficiency of the aging male (PADAM), and the utility of androgen supplementation for older men continue to be vigorously investigated. The potential interest in male HRT for PADAM is based on two major factors: There is a decline in serum testosterone levels as men age and there are concomitant changes in androgen target organs that are reminiscent of what is seen in hypogonadal young adult men before they receive testosterone replacement.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Preview
Unable to display preview. Download preview PDF.
References
Tenover JS. Effects of testosterone supplementation in the aging male. J Clin Endocrinol Metab 1992; 75: 1092–1098.
Morley JE, Perry HM, Kaiser FE, et al. Effects of testosterone replacement therapy in hypogonadal males: a preliminary study. J Am Geriatr Soc, 1993; 41: 149–152.
Vermeulen A. Clinical Review 24: Androgens in the aging male. J Clin Endocrinol Metab 1991; 73: 221–224.
Gary A, Berlin JA, McKinlay J, et al. An examination of research design effects on the association of testosterone and male ageing: results of a meta-analysis. J Clin Epidemiol 1994; 44: 671–684.
Morley JE, Kaiser FE, Perry HM. Et al. Longitudinal changes in testosterone, luteinizing hormone, and follicle-stimulating hormone in healthy older men. Metabolism 1997; 46: 410–413.
Harman SM, Metter EJ, Tobin JD, et al. Longitudinal effects of aging on serum total and free testosterone in healthy men. J Clin Endocrinol Metab 2001; 86: 724–731.
Perry HM, Miller DK, Patrick P, Morley JE. Testosterone and leptin in older African-American men: relationship to age, strength, function, and season. Metabolism 2000; 49: 1085–1091.
Gray A. Feldman HA, McKinlay JB, Longcope C. Age, disease, and changing sex hormone levels in middle-aged men: results of the Massachusetts male aging study. J Clin Endocrinol Metab 1991; 73: 1016–1025.
Santamaria JD, Prior JC, Fleetham JA. Reversible reproductive dysfunction in men with obstructive sleep apnea. Clin Endocrinol, 1988; 28: 461–470.
van den Beld AW, deJong FH, Grobbee DE, et al. Measures of bio-available serum testosterone and estradiol and their relationship with muscle strength, bone density, and body composition in elderly men. J Clin Endocrinol Metab 2000; 85: 3276–3282.
Nilsson P, Moller L, Solkad K. Adverse effects of psychosocial stress on gonadal function and insulin levels in middle aged males. J Intern Med 1995; 237: 479–486.
Khosla S, Melton LJ, Atkinson EJ, et al. Relationship of serum sex steroid levels and bone turnover markers with bone mineral density in men: a key role for bio-available estrogen. J Clin Endocrinol Metab 1998; 83: 2266–2275.
Geller J, Albert J, Lopez D, et al. Comparison of androgen metabolites in benign prostatic hypertrophy (BPH) and normal prostate. J Clin Endocrinol Metab 1976; 43: 686–690.
Vermeulen A, Verdonck L, Kaufman JM. A critical evaluation of simple methods for the estimation of free testosterone in serum. J Clin Endocrinol Metab 1999; 84: 3666–3672.
Forbes GB, Reina JC. Adult lean body mass declines with age: some longitudinal observations. Metabolism, 1970; 19: 653–663.
Larsson LG, Grimby G, Karlsson J. Muscle strength and speed of movement in relation to age and muscle morphology. J Appl Physiol 1979; 46: 451–456.
Bhasin S, Storer TW, Berman N, et al. Testosterone replacement increases fat-free mass and muscle size in hypogonadal men. J Clin Endocrinol Metab 1997; 82: 407–413.
Bhasin S, Storer TW, Berman N, et al. The effects of supraphysiologic doses of testosterone on muscle size and strength in normal men. N Engl J Med 1996; 335: 1–7.
Orwoll ES, Klein RF. Osteoporosis in men. Endocr Rev 1995; 16: 87–116.
Stanley HL, Schmitt BP, Poses RM, Deiss WP. Does hypogonadism contribute to the occurrence of minimal trauma hip fracture in elderly men? J Am Geriatr Soc 1991; 39: 766–771.
Schiavi RC. Androgens and sexual function in men. In: Oddens BJ, Vermeulen A, eds. Androgens and the Aging Male. New York: Parthenon Press, 1996: 111–128.
Kwan M, Greenleaf WJ, Mann J, et al. The nature of androgen action on male sexuality: a combined laboratory-self-report study on hypogonadal men. J Clin Endocrinol Meab 1983; 57: 557–562.
Korenman SG, Morley JE, Mooradian AD, et al. Secondary hypogonadism in older men: its relation to impotence. J Clin Endocrinol Metab 1990; 71: 963–969.
Carani C, Zini D, Baldini A, et al. Effects of androgen treatment in impotent men with normal and low levels of free testosterone. Arch Sex Behav 1990; 19: 223–234.
Wang C, Alexander G, Berman N, et al. Testosterone replacement therapy improves mood in hypogonadal men-a clinical research center study. J Clin Endocrinol Metab, 1996; 81: 3578–3583.
Barrett-Connor E, Von Muhlen DG, Kritz-Silverstein D. Bioavailable testosterone and depressed mood in older men: the Rancho Bernardo Study. J Clin Endocrinol Metab 1999; 84: 573–577.
Janowsky JS, Oviatt SK, Orwoll ES. Testosterone influences spatial cognition in older men. Behav Neurosci 1994; 108: 325–332.
Barrett-Connor E, Goodman-Gruen D, Patay B. Endogenous sex hormones and cognitive function in older men. J Clin Endocrinol Metab 1999; 84: 3681–3685.
Katznelson L, Finkelstein JS, Schoenfeld DA, et al. Increase in bone density and lean body mass during testosterone administration in men with acquired hypogonadism. J Clin Endocrinol Metab 1996; 81: 4358–4365.
Jackson JA, Kleerekoper M, Parfitt AM, et al. Bone histomorphometry in hypogonadal and eugonadal men with spinal osteoporosis, J Clin Endocrinol Metab 1987; 65: 53–58.
Snyder Pi, Peachey H, Hannoush P, et al. Effect of testosterone treatment on bone mineral density in men over 65 years of age. J Clin Endocrinol Metab 1999; 84: 1966–1972.
Kenny AM, Prestwood KM, Gruman CA, et al. Effects of transdermal testosterone on bone and muscle in older men with low bioavailable testosterone levels. J Gerontol Med Sci 2001; 56A: M266–272.
Marin P, Holmang S, Gustafsson C, et al. Androgen treatment of abdominally obese men. Obesity Res 1993; 1: 245–251.
Urban RJ, Bodenburg YH, Gilkison C, et al. Testosterone administration to elderly men increases skeletal muscle strength and protein synthesis. Am J Physiol 1995; 269: E820–826.
Sih R, Morley JE, Kaiser FE, et al. Testosterone replacement in older hypogonadal men: a 12-month randomized controlled trial. J Clin Endocrinol Metab 1997; 82: 1661–1667.
Snyder PJ, Peachey H, Hannoush P, et al. Effect of testosterone treatment on body composition and muscle strength in men over 65 years of age. J Clin Endocrinol Metab 1999; 84: 2647–2653.
Clague JE, Wu FCW, Horan MA. Difficulties in measuring the effect of testosterone replacement therapy on muscle function in older men. Int J Andrology 1999; 22: 261–265.
Bakhshi V, Elliott M, Gentili A, Godschalk M, Mulligan T. Testosterone improves rehabilitation outcomes in ill older men. J Am Geriatr Soc 2000; 48: 550–553.
Crook D. Androgens and the risk of cardiovascular disease. Aging Male 2000; 3: 190–195.
Webb CM, Adamson DL, deZeigler D, Collins P Effect of acute testosterone on myocardial ischemia in men with coronary artery disease. Am J Cardiol 1999; 83: 437–439.
Webb CM, McNeill JG, Hayward CS, et al. Effects of testosterone on coronary vasomotor regulation in men with coronary heart disease. Circulation 1999; 100: 1690–1696.
Hajjar RR, Kaiser RE, Morley JE. Outcomes of long-term testosterone replacement in older hypogonadal males: a retrospective analysis. J Clin Endocrinol Metab 1997; 82: 3793–3796.
Matsumoto AM, Sandblom RE, Schoene RB, et al. Testosterone replacement in hypogonadal men: effects on obstructive sleep apnoea, respiratory drives, and sleep. Clin Endocrinol 1985; 22: 713–721.
Drinka PJ, Jochen AL, Cuisinier M, et al. Polycythemia as a complication of testosterone replacement therapy in nursing home men with low testosterone levels. J Am Geriatr Soc 1995; 43: 899–901.
Shaneyfelt T, Husein R, Bubley G, et al. Hormonal predictors of prostate cancer: a meta-analysis. J Clin Oncol 2000; 18: 847–853.
Smith KW, Feldman HA, McKinlay JB. Construction and field validation of a self-administered screener for testosterone deficiency (hypogonadism) in ageing men. Clin Endocrinol (Osf) 2000; 53: 703–711.
Morley JE. Testosterone replacement and the physiologic aspects of aging in men. Mayo Clin Proc 2000; 75: 583–587.
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2003 Springer Science+Business Media New York
About this chapter
Cite this chapter
Tenover, J.L. (2003). Testosterone and the Older Man. In: Meikle, A.W. (eds) Endocrine Replacement Therapy in Clinical Practice. Contemporary Endocrinology. Humana Press, Totowa, NJ. https://doi.org/10.1007/978-1-59259-375-0_21
Download citation
DOI: https://doi.org/10.1007/978-1-59259-375-0_21
Publisher Name: Humana Press, Totowa, NJ
Print ISBN: 978-1-61737-416-6
Online ISBN: 978-1-59259-375-0
eBook Packages: Springer Book Archive